...
首页> 外文期刊>Journal of Cellular Physiology >Affinity Selection of FGF2-Binding Heparan Sulfates for Ex Vivo Expansion of Human Mesenchymal Stem Cells
【24h】

Affinity Selection of FGF2-Binding Heparan Sulfates for Ex Vivo Expansion of Human Mesenchymal Stem Cells

机译:亲和选择FGF2-Binding乙酰肝素硫酸盐对体外扩张的人类间充质干细胞

获取原文
获取原文并翻译 | 示例
           

摘要

The future of human mesenchymal stem cells (hMSCs) as a successful cell therapy relies on bioprocessing strategies to improve the scalability of these cells without compromising their therapeutic ability. The culture-expansion of hMSCs can be enhanced by supplementation with growth factors, particularly fibroblast growth factor 2 (FGF2). The biological activity of FGF2 is controlled through interactions with heparan sulfate (HS) that facilitates ligand-receptor complex formation. We previously reported on an FGF2-interacting HS variant (termed HS2) isolated from embryonic tissue by anionic exchange chromatography that increased the proliferation and potency of hMSCs. Here, we detail the isolation of an FGF2 affinity-purified HS variant (HS8) using a scalable platform technology previously employed to generate HS variants with increased affinity for BMP-2 or VEGF(165). This process used a peptide sequence derived from the heparin-binding domain of FGF2 as a substrate to affinity-isolate HS8 from a commercially available source of porcine mucosal HS. Our data show that HS8 binds to FGF2 with higher affinity than to FGF1, FGF7, BMP2, PDGF-BB, or VEGF(165). Also, HS8 protects FGF2 from thermal destabilization and increases FGF signaling and hMSC proliferation through FGF receptor 1. Long-term supplementation of cultures with HS8 increased both hMSC numbers and their colony-forming efficiency without adversely affecting the expression of hMSC-related cell surface antigens. This strategy further exemplifies the utility of affinity-purifying HS variants against particular ligands important to the stem cell microenvironment and advocates for their addition as adjuvants for the culture-expansion of hMSCs destined for cellular therapy. J. Cell. Physiol. 232: 566-575, 2017. (c) 2016 Wiley Periodicals, Inc.
机译:未来的人类间充质干细胞(hMSCs)作为一个成功的细胞疗法依靠生物工艺改善策略这些细胞在不损害的可伸缩性他们的治疗能力。可以增强hMSCs补充生长因子,尤其是纤维母细胞生长因子2 (FGF2)。通过与乙酰肝素相互作用控制吗硫酸(HS)中的便利复杂的形成。FGF2-interacting商品变体(称为那么HS2)孤立从胚胎组织通过阴离子交换色谱法,提高了扩散和hMSCs效力。隔离的FGF2 affinity-purified商品变体使用一个可伸缩的平台技术(HS8)以前用来生成商品变体增加亲和力BMP-2或VEGF(165)。过程的肽序列使用heparin-binding FGF2作为衬底的领域从一个商业affinity-isolate HS8可用的猪粘膜商品来源。表明HS8结合FGF2高亲和力比FGF1, FGF7、BMP2 PDGF-BB或VEGF(165)。同时,HS8保护FGF2热不稳定和增加FGF信号hMSC扩散通过FGF受体1。长期与HS8文化的补充hMSC数字和他们的增加克隆形成没有不利影响hMSC-related细胞的表达表面抗原。是affinity-purifying HS的效用变异对特定的配体很重要干细胞微环境和倡导他们的佐剂culture-expansion hMSCs注定细胞治疗。(c) 2016年威利期刊公司。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号